Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1

Abstract

BackgroundThe novel gene HA117 is a multidrug resistance (MDR) gene expressed by all-trans retinoic acid-resistant HL-60 cells. In the present study, we compared the multidrug resistance of the HA117 with that of the classical multidrug resistance gene 1 (MDR1) in breast cancer cell line 4T1.MethodsTransduction of the breast cancer cell line 4T1 with adenoviral vectors encoding the HA117 gene and the green fluorescence protein gene (GFP) (Ad-GFP-HA117), the MDR1 and GFP (Ad-GFP-MDR1) or GFP (Ad-GFP) was respectively carried out. The transduction efficiency and the multiplicity of infection (MOI) were detected by fluorescence microscope and flow cytometry. The transcription of HA117 gene and MDR1 gene were detected by reverse transcription polymerase chain reaction (RT-PCR). Western blotting analysis was used to detect the expression of P-glycoprotein (P-gp) but the expression of HA117 could not be analyzed as it is a novel gene and its antibody has not yet been synthesized. The drug-excretion activity of HA117 and MDR1 were determined by daunorubicin (DNR) efflux assay. The drug sensitivities of 4T1/HA117 and 4T1/MDR1 to chemotherapeutic agents were detected by Methyl-Thiazolyl-Tetrazolium (MTT) assay.ResultsThe transducted efficiency of Ad-GFP-HA117 and Ad-GFP-MDR1 were 75%-80% when MOI was equal to 50. The transduction of Ad-GFP-HA117 and Ad-GFP-MDR1 could increase the expression of HA117 and MDR1. The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells. There were no significant differences in drug sensitivity between 4T1/HA117 and 4T1/MDR1 for the P-gp substrates (ADM, VCR and Taxol) (P < 0.05), while the difference between them for P-gp non-substrate (BLM) was statistically significant (P < 0.05). DNR efflux assay confirmed that the multidrug resistance mechanism of HA117 might not be similar to that of MDR1.ConclusionsThese results confirm that HA117 is a strong MDR gene in both HL-60 and 4T1 cells. Furthermore, our results indicate that the MDR mechanism of the HA117 gene may not be similar to that of MDR1.

2′-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer

“…Since resistance to PX remains a significant unmet problem, the ability of BTM NPs to address this problem may be very promising. Unfortunately, the 4T1 murine cell line in this study is not resistant [33]. However, the 4T1 cell line was very aggressive based on the facts that 1) the tumor size of untreated mice reached ~1500 cm 3 after 20–25 days of cell injection; 2) the Q4d × 4 treatment with Taxol at MTD of 25 mg/kg did not show better antitumor inhibition effect compared to untreated mice (Figure 8B).…”

Study of the mechanisms underlying the reversal of multidrug resistance of human neuroblastoma multidrug-resistant cell line SK-N-SH/MDR1 by low-intensity pulsed ultrasound

“…Recombinant adenoviral vectors expressing green fluorescence protein gene (GFP) and multidrug resistance gene 1 (MDR1) (Ad-GFP-MDR1) and only GFP (Ad-GFP) were previously prepared in our laboratory (13). HEK 293 cells transducted with an appropriate multiplicity of infection (MOI) of Ad-GFP-MDR1 and Ad-GFP were harvested and frozen using a dry ice/methanol bath, immediately thawed in a 37˚C water bath and vortexed.…”

Clathrin light chain‐conjugated drug delivery for cancer

“…Therapeutic effects of CLC‐PTX conjugates were studied in BALB/c mice bearing 4T1 breast cancer, which is refractory to antineoplastic agents. 36 , 37 At 13 days following implantation of 1 × 10 5 4T1 cells—the timepoint when the tumor volume reached ~100 mm 3 —the mice were divided randomly into three groups. Each group received either PBS, free PTX, or CLC‐PTX twice per week iv for 2 weeks (equivalent amount of PTX, 8 μg/kg/injection).…”